GLP-1 Agonists Stocks
Metabolic health innovators focus on the development, delivery, and ancillary support of glucagon-like peptide-1 receptor agonists designed to address global obesity and type 2 diabetes epidemics.
As of Oct 23, 2026, GLP-1 Agonists has 28 US-listed companies worth $1.3T combined. The median member moved -2.3% over the past week; KLRA led among the 25 largest at +14.2% and AARD trailed at -63.2%.
Companies in GLP-1 Agonists
- LLY – Eli Lilly and Company, $1.1T
- NVO – Novo Nordisk A/S, $172B
- HIMS – Hims Hers Health Inc, $6.8B
- VKTX – Viking Therapeutics Inc, $3.3B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- OMDA – Omada Health, Inc. Common Stock, $1.1B
- ALT – Altimmune Inc, $595M
- ORMP – Oramed Pharmaceuticals Inc, $171M
- WW – WW International, Inc, $142M
- LFMD – LifeMD Inc, $109M
- AARD – Aardvark Therapeutics, Inc. Common Stock, $104M
- VANI – Vivani Medical Inc., $104M
- RANI – Rani Therapeutics Holdings Inc, $103M
- AIRS – Airsculpt Technologies Inc, $91.9M
- LFVN – Lifevantage Corporation, $76.4M
- IBIO – iBio, Inc. Common Stock, $72.3M
- BMEA – Biomea Fusion Inc, $50M
- VERU – Veru Inc, $41.9M
- GUTS – Fractyl Health, Inc. Common Stock, $20.6M
- BPTSY – Biophytis S.A., $17.5M
- LPCN – Lipocine Inc, $16.9M
- MTVA – MetaVia Inc., $9.6M
- MGRX – Mangoceuticals, Inc. Common Stock, $6.4M
- LEXX – Lexaria Bioscience Corp, $5.5M
- ELAB – Elevai Labs, Inc. Common Stock, $3.7M
- ALUR – Allurion Technologies, Inc., $342,107